Media stories about ZIOPHARM Oncology (NASDAQ:ZIOP) have been trending somewhat positive on Saturday, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.907744167312 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Ziopharm Gets Hit With Clinical Hold, Like All Other CAR-T Safety Precautions This Too Shall Pass (seekingalpha.com)
- ZIOPHARM Oncology (ZIOP) Downgraded by JPMorgan Chase & Co. (americanbankingnews.com)
- ZIOPHARM Oncology Inc. (ZIOP) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- JPMorgan Downgrades ZIOPHARM Oncology (ZIOP) to Underweight (streetinsider.com)
- Why Ziopharm Oncology is Crashing by 17.7% Today (finance.yahoo.com)
ZIOPHARM Oncology traded down $0.10, reaching $3.19, during trading on Friday, Marketbeat.com reports. 2,419,677 shares of the stock were exchanged, compared to its average volume of 1,623,658. ZIOPHARM Oncology has a twelve month low of $3.10 and a twelve month high of $6.67. The company has a market cap of $469.32 million, a P/E ratio of -6.02 and a beta of 1.70.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The business had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $1.55 million. equities analysts predict that ZIOPHARM Oncology will post -0.52 EPS for the current year.
ZIOP has been the topic of several recent analyst reports. JPMorgan Chase & Co. lowered ZIOPHARM Oncology from a “neutral” rating to an “underweight” rating in a research note on Monday, June 18th. BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. ValuEngine upgraded ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Zacks Investment Research downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.50 target price on shares of ZIOPHARM Oncology in a report on Monday, May 14th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $5.25.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.